# A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

> **NCT06899217** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CinDome Pharma, Inc.** · enrollment: 416 (actual)

## Conditions studied

- Idiopathic Gastroparesis

## Interventions

- **DRUG:** CIN-102 Dose 15mg
- **DRUG:** Placebo
- **DRUG:** CIN-102 Dose 10mg

## Key facts

- **NCT ID:** NCT06899217
- **Lead sponsor:** CinDome Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-29
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06899217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06899217, "A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06899217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*